Background Vorapaxar is a protease\activated receptor\1 antagonist approved by the U.
Background Vorapaxar is a protease\activated receptor\1 antagonist approved by the U. MI, or heart stroke was significantly decreased with vorapaxar weighed against placebo (7.9% versus 9.5%, HR, 0.80; 95% CI 0.73 to 0.89; of sufferers VX-689 with prior heart stroke or TIA3C5; nevertheless, the results in the precise inhabitants for whom the FDA accepted vorapaxar … [Read more…]